Investment Thesis
Lisata Therapeutics is a pre-revenue pharmaceutical company with only $170K in annual revenue (down 83% YoY), burning $15.9M in operating cash flow annually against just $16M in total cash reserves. At the current burn rate, the company has approximately 12 months of cash runway with no clear path to profitability or revenue generation.
Strengths
- Strong liquidity position with 5.76x current ratio and 5.07x quick ratio
- Zero long-term debt with conservative capital structure
- Stockholders' equity of $14.9M provides cushion against insolvency
Risks
- Minimal revenue ($170K) with 83% YoY decline indicates failed commercialization or pipeline delays
- Annual operating cash burn of $15.9M against $16M cash reserves (approximately 12-month runway)
- Deeply negative profitability metrics across all measures (operating margin -10,711%, net margin -9,757%)
- Nine Form 4 insider filings in 90 days suggest elevated uncertainty or potential capital structure concerns
Key Metrics to Watch
- Monthly cash burn rate and updated cash runway calculations
- Revenue trajectory and new product commercialization milestones
- Clinical trial progression and regulatory approvals for pipeline candidates
Financial Metrics
Revenue
170.0K
Net Income
-16.6M
EPS (Diluted)
$-1.91
Free Cash Flow
-16.0M
Total Assets
17.7M
Cash
16.0M
Profitability Ratios
Gross Margin
1,012.5%
Operating Margin
-10,711.2%
Net Margin
-9,756.5%
ROE
-111.7%
ROA
-93.5%
FCF Margin
-9,398.2%
Balance Sheet & Liquidity
Current Ratio
5.76x
Quick Ratio
5.07x
Debt/Equity
0.00x
Debt/Assets
17.7%
Interest Coverage
N/A
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-12T20:36:22.457998 |
Data as of: 2025-12-31 |
Powered by Claude AI